Fresenius Kabi and TQ Therapeutics Forge Strategic Cell Therapy Technology Agreement

Advancing Cell & Gene Therapy Accessibility

Fresenius Kabi, a global healthcare company, has announced a landmark partnership with TQ Therapeutics to accelerate innovation in cell and gene therapy. The agreement grants Fresenius Kabi exclusive licensing rights to leverage TQ’s proprietary cell selection technology, enhancing its manufacturing capabilities and distribution reach.

Key Highlights

• Partnership Scope: Exclusive license for Fresenius Kabi to develop, manufacture, and distribute products using TQ’s cell selection technology.
• Strategic Objective: Scale manufacturing of advanced cell and gene therapies to improve patient access globally.
• Technology Advantage: TQ’s proprietary platform enables more efficient and precise cell selection, critical for therapies like CAR-T and other personalized treatments.
• Market Impact: Strengthens Fresenius Kabi’s role in next-generation therapies, complementing its existing portfolio in transfusion medicine and clinical nutrition.
• Patient Benefit: Improved scalability and efficiency will help reduce costs and expand availability of cutting-edge therapies.

This collaboration underscores Fresenius Kabi’s commitment to innovation in life sciences and positions both companies at the forefront of the rapidly evolving cell therapy market.

Sources: Business Wire, Fresenius Kabi Press Release; Fresenius SE & Co. KGaA Public Disclosure